仁和藥業(000650.SZ):擬以5787萬元購買北京東城區的相關房產 作為自用辦公場所
格隆匯9月29日丨仁和藥業(000650.SZ)公佈,公司第八屆董事會第二十三次臨時會議決議,審議通過了《關於全資子公司購買房產作為自用辦公場所的議案》 ;
隨着公司發展規模的不斷擴大,人員規模、業務領域也隨之增加。為改善辦公環境,提高工作效率,適應公司經營發展需要,樹立良好企業形象,同意公司全資子公司江西仁和藥業有限公司(含其子公司)與北京鐘鼓樓龍苑文化發展有限公司簽署相關協議,擬以5787萬元人民幣(實際價格以簽訂的房屋銷售合同為準),購買北京東城區舊鼓樓大街P保護區用地項目第R4-1、R4-2、R4-3號院落(該院落編號僅為項目施工編號,最終以政府主管部門核准的門牌號為準。該院落產權的用地性質為商業), 作為公司辦公場所,並授權該公司按法定程序辦理購買的相關手續。
根據《深圳證券交易所股票上市規則》《公司章程》等相關規定,此次交易在公司董事會審批權限範圍內,無需提交股東大會審議。此次購買房產不構成關聯交易,亦不構成《上市公司重大資產重組管理辦法》規定的重大資產重組,無需經過有關部門的批准。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.